Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636373 · ClinicalTrials.gov registry record · Phase 4
Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
A Phase 4 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03636373 is a Phase 4 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 5 participants.
The verdict
NCT03636373, a Phase 4 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-10-25 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03636373
The ClinicalTrials.gov registry entry for NCT03636373 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT03636373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03636373 about?
NCT03636373 is a clinical study titled "Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout". The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
What is the current status of trial NCT03636373?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2019-10-25. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT03636373?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT03636373?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.